



“Providing an opportunity for multiple myeloma patients and their loved ones to come together to exchange information for mutual support, comfort, and friendship”

Meeting: **Meetings will resume when we are allowed to gather at the address below.**

451 Junction Road
Madison, WI
UW West Clinic Room 1287

Enter the clinic... turn left and walk down a short hall...turn left again and conference room 1287 is the last one on the left.

Group Information:

Jayne Schwartz 608- 244-2120
schwartzdon@sbcglobal.net

Madison Multiple Myeloma Support Group website
madisonmultiplemyeloma.org

Mailing Address: Wisconsin Multiple Myeloma Support Group
3309 Chicago Avenue Madison, WI 53714-1815

Information Sources :

International Myeloma Foundation (IMF)
Phone: 800 - 452 - 2873
Email: TheIMF@myeloma.org
Website: www.myeloma.org

Multiple Myeloma Research Foundation(MMRF)
Phone: 203 - 972 - 1250
Email: info@themmrf.org
Website: www.multiplemyeloma.org

Upcoming Meeting Speakers... Mark your calendars now!

Dr Natalie Callander, UW Carbone Cancer Center will join us at our October meeting. This will likely be a virtual presentation.

The status of our in-person support group meeting is still undetermined. I have reached out to other support groups that meet at UW facilities to see if they have any information about when and how our meetings might resume. What will they look like moving forward? Will there be limited numbers of people to attend meetings? Will there be requirements like hand sanitizers, masks, etc.? Will there be a reduction of meeting time? I will keep you updated as I learn more.

The annual **Multiple Myeloma Patient and Caregiver Symposium** that has previously been held in in Pewaukee, WI will be a virtual event this year. It is scheduled for September 19th. More details to follow from our contact, Maria Voermans, Froedert Hospitals and Clinics. I will keep you posted as I learn more.

Another new drug on the horizon.....

Early Data for Teclistamab Shows Deep Responses in Myeloma

FRIDAY, MAY 29, 2020

Sources: [Janssen Pharmaceuticals press release](#), May 18, 2020; [ClinicalTrials.Gov](#), May 20, 2020; [Endpoints News](#), May 18, 2020.

Janssen Pharmaceuticals has reported preliminary results from the first-in-human phase I dose escalation study of teclistamab for patients with relapsed or refractory multiple myeloma. Teclistamab is an investigational bispecific antibody targeting both B-cell maturation antigen and CD3 receptors on T-cells. The treatment achieved a 67% overall response rate among 12 patients who received the highest dosage, with 3 of the patients achieving a complete response. The full results of the clinical trial will be reported at the ASCO20 Virtual Scientific Program.

The study enrolled adult patients with multiple myeloma who had received a median of six prior lines of treatment, had previously been treated with a proteasome inhibitor and an immunomodulatory drug, and had relapsed or were refractory to established therapies. Patients were treated with teclistamab at varying doses, ranging from 0.3-270 µg/kg. Of the 78 patients who were administered teclistamab, 21 responded to the treatment. Responses were found to be deep and persistent and, at the time of data cutoff, 16 of the 21 patients had an ongoing response.

The most common adverse events occurring in >20% of patients were anemia, cytokine release syndrome, neutropenia, thrombocytopenia, and pyrexia. One death occurred, which the team concluded was not related to treatment.

Researchers are currently working on a dosage expansion study to test the highest range of teclistamab that can be safely administered.

IMF Info Line – If you or someone you care for has Myeloma, you have questions. Probably, lots of them. You can search the Internet all you want, but other than asking your doctor, there is no better way to get your questions answered than to call the IMF Info Line. Missy, Judy and Paul know their stuff and they want to share what they know with you. Just ask anyone who has called the IMF Info Line. Patients or caregivers are welcome to contact the Info Line staffed by trained specialists at 800-452-CURE (800-452-2873). The Info Line is staffed between 9am and 4pm Pacific Time, 11am to 6pm Central time or infoline@myeloma.org.

The Trillium Fund was established by our founding support group members to facilitate Multiple Myeloma research here in Madison at the Wisconsin Institute of Medical Research. If you or your family wish to donate or send a memorial to this program, checks can be made payable to the “UW Foundation – Trillium Fund” and sent to UW Carbone Cancer Center, University of Wisconsin Foundation, 1848 University Ave, Madison, WI 53726. Donations may also be made online at www.supportuw.org/give (Trillium Fund in Multiple Myeloma Research – 112903576). For any questions, please call Daniel Rosen at (608) 264-5437 or email curecancer@supportuw.org.